E-cadherin Deficiency Initiates Gastric Signet-ring Cell Carcinoma in Mice and Man
Overview
Affiliations
The importance of loss of the cell-cell adhesion molecule E-cadherin (encoded by CDH1) to tumor progression is well established. However, CDH1 germ-line mutations predispose to the cancer susceptibility syndrome hereditary diffuse gastric cancer (HDGC), suggesting a role for E-cadherin in tumor initiation. The earliest indications of cancer in the stomachs of CDH1 mutation carriers are microscopic foci of intramucosal signet-ring cell carcinoma (SRCC; designated "eHDGC"). Here, we used N-methyl-N-nitrosourea (MNU) to promote gastric carcinogenesis in wild-type (wt) and cdh1(+/-) mice. MNU induced a variety of gastric tumors; however, intramucosal SRCC developed with an 11 times higher incidence in cdh1(+/-) mice compared with wt mice. The murine SRCC resembled the human eHDGCs in that they were hypoproliferative, lacked nuclear beta-catenin accumulation, and had reduced membrane localization of E-cadherin and its interacting junctional proteins. The down-regulation of E-cadherin in the murine SRCCs confirmed the importance of the second CDH1 hit to the initiation of diffuse gastric cancer. CDH1 promoter hypermethylation has been proposed to be a major second hit in advanced HDGC; however, its contribution to eHDGC was unknown. We thus examined a series of human eHDGC and detected CDH1 promoter methylation in 50% of foci. Promoter methylation was accompanied by reduced wt CDH1 mRNA levels in the foci and had a monoclonal pattern, consistent with an epigenetic initiation of disease. Together, these findings provide compelling evidence for a deficiency in cell-to-cell adhesion being sufficient to initiate diffuse gastric cancer in the absence of hyperproliferation and beta-catenin activation.
Shadi Vaziri S, Tajbakhsh E, Khamesipour F, Momtaz H, Mazaheri Z Rep Biochem Mol Biol. 2025; 13(2):263-272.
PMID: 39995644 PMC: 11847590. DOI: 10.61186/rbmb.13.2.263.
Wang J, Xiu J, Battaglin F, Arai H, Soni S, Zhang W NPJ Precis Oncol. 2024; 8(1):214.
PMID: 39349771 PMC: 11442451. DOI: 10.1038/s41698-024-00694-8.
Capuano A, Vescovo M, Canesi S, Pivetta E, Doliana R, Nadin M Gastric Cancer. 2024; 27(5):1016-1030.
PMID: 38941035 PMC: 11335817. DOI: 10.1007/s10120-024-01528-z.
Lin J, Chen Z, Guo G, Chen X World J Gastrointest Oncol. 2024; 16(3):687-698.
PMID: 38577442 PMC: 10989384. DOI: 10.4251/wjgo.v16.i3.687.
Green B, Gamble L, Diggs L, Nousome D, Patterson J, Joughin B Mol Cancer Res. 2023; 21(12):1356-1365.
PMID: 37707375 PMC: 10840796. DOI: 10.1158/1541-7786.MCR-23-0122.